TCT 2022 | RADIANCE II Pivotal Trial

Renal denervation has been developed to treat blood hypertension. Even though at present is still not common, with the development of new technology and improved technique, its results are promising. 

TCT 2022

The RADIANCE II Pivotal included 224 patients. 150 received renal denervation with ultrasound (uRDN) and 74 went to the control group.

Efficacy primary end point was ambulatory systolic blood pressure at 2 months. 

Mean age was 55, 25% were women, 6% diabetic, 5% had prior hospitalization for hypertensive crisis. 

Office systolic BP was 155/100 mmHg and they only received one antihypertensive drug. 

There were no complications during the procedure, or at 6 months. 

Primary end point resulted in favor of uRDN: -7.9 mmHg vs. 1.8 mmHg p<0.0001.

Read also: TCT 2022 | FRANCE-TAVI Registry: Small Annuli.

At 2 months, those receiving uRDN presented lower systolic and diastolic ambulatory BP, both day and nighttime office measurements. 

uRDN did not alter renal function at 2 month follow up. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Primary Results of the Randomized, Sham-Controlled RADIANCE II Pivotal Trial.

Presenter: Ajay Kirtan.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACURATE Neo2 Underexpansion: Prevalence and Clinical Implications

While transcatheter aortic valve replacement (TAVR) provides durable clinical benefits across a wide range of patients, technical challenges remain that may affect long-term outcomes....

Spontaneous Left Main Dissection: Clinical Characteristics, management and Outcomes

Courtesy of Dr. Juan Manuel Pérez. Spontaneous left main dissection in an uncommon, and potentially life-threatening, cause of acute MI. The aim of this study,...

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...